MARK COHEN: Open Payments
NPI 1164434015 · LANCASTER, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,163 in 105 payments from 26 companies in 2025. Trend: 2023 $1,297 · 2024 $1,522 · 2025 $2,163
Food & beverage: $2,163
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 13 | $286 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 7 | $172 |
| Otsuka America Pharmaceutical, Inc. | 11 | $161 |
| Bayer Healthcare Pharmaceuticals Inc. | 8 | $154 |
| Lundbeck LLC | 7 | $152 |
| PFIZER INC. | 9 | $141 |
| Ardelyx, Inc. | 5 | $124 |
| ABBVIE INC. | 6 | $122 |
| Astellas Pharma US Inc | 6 | $111 |
| AstraZeneca Pharmaceuticals LP | 6 | $102 |
Products named: REXULTI, Wegovy, CAPLYTA, Kerendia, IBSRELA, Veozah, NURTEC ODT, Dexcom G6 Transmitter.
Industry payments across PA — which companies pay providers there.
